Research

Why Research?

Many of our patients would agree that Sleep Disorders can have a major effect on one’s quality of life.  Unfortunately, many of the current treatments for these conditions don’t target the cause of the issue, rather they just mask the underlying condition.  The field of Sleep Research focuses on developing a treatment that will target the sleep disorder, and the symptoms improve as a result.  

What are the BENEFITS of participating in Research?

Our Research studies can be beneficial to our patients in the following ways:

  1. Participants are able to receive investigational treatment for their conditions that may result in improvement in their symptoms.
  2. If eligible for a study, participants may receive medical treatment at no cost to them.
  3. Participants may be reimbursed for their time and effort during the study.
  4. Participants can contribute to the availability of new drugs that may be more effective than current drug therapy.

What Studies are available for me to participate in?

 

TAK 925-2002

TAK 925-2002 is a new investigational drug that is being tested to see if it could potentially be a safe and effective way to help increase wakefulness. The purpose of this study is to evaluate the safety and tolerability of administering a single intravenous (IV) infusion dose of TAK 925-2002 to participants with idiopathic hypersomnia. Must meet all inclusion criteria to participate.

Qualifications to participate in this study:

  • Are 18-75 years old.
  • have been diagnosed with idiopathic hypersomnia (IH)
  • First experienced the effects of hypersomnia when you were between 10 and 30 years of age.
  • Meet additional requirements as determined by a screening process.

TAK 0001

This study will look at whether portable devices can provide measurements at home similar to those taken in the clinic, focusing on participants diagnosed with Narcolepsy Type 1. The goal of this type of research is to develop more at-home testing alternatives for those who need this type of measurements.

Qualifications to participate in this study:

  • 16 – 60 Years old (<18 parental assent)
  • Must have access to at-home wi-fi
  • Diagnosed with Narcolepsy with cataplexy (N1)
  • Must meet additional requirements as determined by screening process.

TAK 994-1501

TAK 994-1501 is a new investigational drug being tested in people with narcolepsy with cataplexy. The main purpose of the study is to see how tolerable and safe the investigational drug is and how it may affect this diagnosis. Must meet all inclusion criteria to participate.

Qualifications to participate in this study:

  • Are 18-65 years old
  • Have been diagnosed with narcolepsy with cataplexy (also known as narcolepsy type1)
  • Are willing to stop taking narcolepsy medications during study participation
  • Go to bed between 9 pm and midnight
  • Meet additional requirements as determined by a screening process

SUVEN

This study is for a new oral drug that may help stimulate histamine receptors in the brain. Histamine receptors play a role in arousal mechanisms in the brain such as wakefulness. Subjects that enroll are helping study the effectiveness of this drug specifically for Narcolepsy Type 1 and 2. Must meet all inclusion criteria to participate.

Qualifications to participate in this study:

  • 18 to 50 years of age
  • Diagnosed with narcolepsy with or without cataplexy (N1 or N2)
  • Have had a Multiple Sleep Latency Test (MSLT) within the previous 15 years with results that meet study entry requirements
  • Must meet additional requirements as determined by a screening process

TAK 994-1501

TAK 994-1501 is a new investigational drug being tested in people with narcolepsy with cataplexy. The main purpose of the study is to see how tolerable and safe the investigational drug is and how it may affect this diagnosis. Must meet all inclusion criteria to participate.

Qualifications to participate in this study:

  • Are 18-65 years old
  • Have been diagnosed with narcolepsy with cataplexy (also known as narcolepsy type1)
  • Are willing to stop taking narcolepsy medications during study participation
  • Go to bed between 9 pm and midnight
  • Meet additional requirements as determined by a screening process

SUVEN

This study is for a new oral drug that may help stimulate histamine receptors in the brain. Histamine receptors play a role in arousal mechanisms in the brain such as wakefulness. Subjects that enroll are helping study the effectiveness of this drug specifically for Narcolepsy Type 1 and 2. Must meet all inclusion criteria to participate.

Qualifications to participate in this study:

  • 18 to 50 years of age
  • Diagnosed with narcolepsy with or without cataplexy (N1 or N2)
  • Have had a Multiple Sleep Latency Test (MSLT) within the previous 15 years with results that meet study entry requirements
  • Must meet additional requirements as determined by a screening process

 

***If your condition is not listed, please continue to check our page! New studies may become available that are beneficial to you.***

Where can I find more information?

If you would like more information about our Research Department, please contact our team. We would love to hear from you!

Clinical Research Coordinator

Kim Bowyer, MS
(803) 251-3093 ext. 119
Kim.Bowyer@bogansleep.com

Research@BoganSleep.com

Clinical Research Associate

Brittany Barfield
Clinical Research Associate
(803) 251-3093  ext.117
 

Clinical Research Associate

Lacey Tisdale
Clinical Research Associate
Lacey.Tisdale@BoganSleep.com
 
 

Clinical Research Coordinator

Dara Brown, MPH
(803) 251-3093 ext. 136
Dara.Brown@BoganSleep.com

Research@BoganSleep.com

Contact Us

Our Location

Office Hours
Monday: 08:30 AM - 05:00 PM
Tuesday: 08:30 AM - 05:00 PM
Wednesday: 08:30 AM - 05:00 PM
Thursday: 08:30 AM - 05:00 PM
Friday: 08:30 AM - 12:00 PM
Saturday: Closed
Sunday: Closed
Sleep Lab: 08:00 PM - 06:00 AM
After Hours Sleep Lab Phone Number:
(803) 765-9461